Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.

Multi-center, Open, Non-intervention and Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab. in Patients With Type 2 Diabetes

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04326166

Enrollment

1971

Registered

2020-03-30

Start date

2020-03-25

Completion date

2021-07-31

Last updated

2021-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

Multi-center, open, non-intervention and observational study to Evaluate the efficacy and safety of Suganon tab. or Sugamet XR tab. in patients with Type 2 diabetes

Interventions

DRUGEvogliptin

Evogliptin

DRUGMetformin and Evogliptin

Metformin and Evogliptin

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

19 Years to No maximum

Healthy volunteers

Inclusion criteria

1. The subject is aged ≥19 years 2. The subject has type 2 diabetes mellitus

Exclusion criteria

1\. The subject has a contraindication

Design outcomes

Primary

Measure	Time frame	Description
Change in HbA1c	at 12 weeks	To assess change from baseline in HbA1c

Secondary

Measure	Time frame	Description
Change in HbA1c	at 24 weeks	To assess change from baseline in HbA1c
The percentage of patients with HbA1c <7.0% and <6.5%	at 12 and 24 weeks	To assess the percentage of patients with HbA1c \<7.0% and \<6.5%
Change in FPG	at 12 and 24 weeks	To assess change from baseline in fasting plasma glucose (FPG)

Countries

South Korea

Contacts

Primary ContactJongchul Won, M.D., Ph.D.

dronjc@gmail.com+82-2-950-8860

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026